Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Brigham and Women's Hospital
Adela, Inc
Case Comprehensive Cancer Center
Massive Bio, Inc.
AVM Biotechnology Inc
Nurix Therapeutics, Inc.
Arcus Biosciences, Inc.
Washington University School of Medicine
Tempus AI
Assistance Publique Hopitaux De Marseille
Seagen Inc.
Taproot Health
Cancer Support Community, Research and Training Institute, Philadelphia
Celldex Therapeutics
Fate Therapeutics
Fate Therapeutics
Leiden University Medical Center
Genzada Pharmaceuticals USA, Inc.
Ascentage Pharma Group Inc.
Hospital Universitario San Ignacio
Eutilex
Incyte Corporation
Hospices Civils de Lyon
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Shenzhen Geno-Immune Medical Institute
MultiVir, Inc.
Shenzhen BinDeBio Ltd.
University of California, San Diego
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Asan Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stanford University
Rutgers, The State University of New Jersey
INSYS Therapeutics Inc
University of Chicago
National Cancer Institute (NCI)
Altor BioScience
Memorial Sloan Kettering Cancer Center
Novartis
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Cancer Research UK
Case Comprehensive Cancer Center